ABSTRACT The fate oftwo recently described human B lymphocyte-specific antigens (Bi and B2) was studied after B-cell activation in vivo and in vitro. Whereas both BI and B2 were present on virtually all B cells from normal lymph nodes, B2 was absent from approximately 50% ofB cells from hyperplastic lymph nodes. When B cells from spleen, tonsil, or peripheral blood were stimulated in vitro with pokeweed mitogen, activated cells were found to lose B2 (days 4-5) and subsequently BI (days 6-7). Temporally, B2 loss was accompanied by loss ofsurface IgD, expression ofT1O, and the development of intracytoplasmic IgM; Bi loss was correlated with the acquisition of surface IgG and the appearance of intracytoplasmic IgG. Peripheral blood B cells, on which B2 is normally onlywealdy expressed (B1++++B2+) in contrast to B cells from secondary lymphoid organs (B1++++B2++), exhibited a transitory increase in B2 expression to the Bl++++B2++ phenotype prior to B2 disappearance during activation. Taken together with other findings, this observation suggests that peripheral blood may contain a relatively immature subpopulation of B cells.
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In several previous studies (1) (2) (3) , two human B cell-specific antigens, designated B1 and B2, were identified and characterized with the use of monoclonal antibodies. B1 is present on >95% of B cells in peripheral blood and lymphoid organs; it is absent from resting and activated T cells, monocytes, and granulocytes (1) . B1 is expressed on virtually all tumors of B-cell origin with the exception of myeloma, and it is also found on a proportion of non-T non-B acute lymphatic leukemia cells which possess "pre-B" cell characteristics (2) . B2 has a similar pattern of cellular distribution; however, in contrast to B1, B2 is only weakly expressed on peripheral blood B cells and on some but not all lymph node cells. B2 is strongly represented on tonsil and spleen cells (3) . In addition, B2 shows heterogeneous expression on B-cell malignancies. B2 is present on most chronic lymphatic leukemia cells (90%), approximately 50% of both diffuse and nodular poorly differentiated lymphomas, and 10% of acute lymphatic leukemia cells but is absent in Burkitt lymphoma, Waldenstrom macroglobulinemia, and myeloma (4) . Both B1 and B2 are distinct from standard B-cell markers, including Ig isotypes, C3 and Fc receptors, and DR (Ia-like) antigens (1, 3) . Molecular weights of 30,000 and 140,000 have been assigned to B1 and B2, respectively (3) .
The differential representation of B2 and, to a lesser extent, B1 on B-cell tumors and the diminisheJ reactivity of B2 on B cells from peripheral blood and some lymph node samples has led us to investigate the possibility that B1 and B2 are human B-cell differentiation antigens. In the present studies, the fate of B1 and B2 was studied subsequent.to B-cell MATERIALS AND METHODS Monoclonal Antibodies. The production and characterization of monoclonal anti-B1 and anti-B2 have been described (1, 3) . Additional monoclonal antibodies used included: T3 (5) (anti-T cell); Mol (6) (anti-monocyte, anti-peripheral mononuclear leukocyte), and Mo2 (6) (anti-monocyte), kindly provided by R. Todd (Sidney Farber Cancer Institute, Boston); 1-2 (7) [anti-DR (Ia-like) framework antigen]; antibodies specific for human K or A light chain, IgM, IgG, and IgD, kindly provided by Vic Raso (Sidney Farber Cancer Institute). All antibodies were utilized in the ascites form.
Normal Human Tissue. Human tissue specimens were obtained during surgery. Tonsil cells were obtained at the time of routine tonsillectomy. Lymph node tissue, taken for diagnostic biopsy, was considered to be nonmalignant based on histologic features and cell surface markers. Splenocytes were obtained from patients who had sustained traumatic rupture. All tissue specimens were immediately placed in medium containing 5% fetal calf serum, finely minced with forceps and scissors, and made into single-cell suspensions by extrusion through stainless steel mesh. Cell samples were cryopreserved and thawed as needed.
Isolation of Lymphocyte Populations. Human peripheral blood mononuclear cells were isolated from healthy volunteer donors by Ficoll/Hypaque centrifugation. Unfractionated mononuclear cells were separated into surface Ig-positive (sIg+) (B) and sIg-(T plus null) populations by anti-F(ab')2-Sephadex G-200 chromatography (8) with modifications designed to minimize monocyte retention by the column. In brief, purified rabbit anti-human F(ab')2 was pepsin-digested and chromatographed on Sephadex G-150 to remove undigested material.
The F(ab')2 anti-human F(ab')2 fragments were then coupled to CNBr-activated Sephadex G-200. Peripheral blood mononuclear cells were preincubated at 37°C for 1 hr to remove cellbound serum IgG (9) , and cells were then applied to the anti-F(ab')2 column and fractionated as outlined (8 (Table 1 ). In contrast, fewer cells stained with anti-B2 than with anti-K/A for all B cell-containing tissues. These differences were significant for lymph node (P < 0.005), spleen (P < 0.05), and tonsil (P < 0.05); a similar trend was also seen with peripheral blood. However, it should be noted that precise enumeration of B cells staining with anti-B2 in blood was difficult due to the low representation of B2 on this tissue. No significant staining of thymus was seen with any B-cell reagent. At least on a gross level, therefore, we find evidence for heterogeneity ofreactivity of anti-B2 on the B-cell population from various lymphoid organs.
The results for lymph node cells in Table 1 on day 3-4 of culture and was virtually complete by day 5 (16) . Stimulation of peripheral blood B cells with PWM was also carried out (n = 2), utilizing a 1:1 ratio of purified B cells and mitomycin C-treated T cells as described (17) . (Fig. 1) .
Correlation of Bi and B2 Loss with Surface Phenotype and clg Production. Several experiments were carried out to determine whether B1 and B2 disappearance might correlate with 1A) ; + + +, moderate-strong, similar to anti-B1 (Fig. 1B) ; + +, moderate, similar to anti-B2 (Fig. 1A) ; +, weak, similar to anti-B2 (Fig.   2A) (21, 22) . For human B lymphocytes, many phenotypic markers have been used toward this end, including sIg and cIg isotype(s) (23, 24) , Fc and C3 receptors (25, 26) , and Ia-like (DR) antigens (26, 27 (16) . Moreover, the majority of B cells in blood bear both sIgM and sIgD (18, 19) . Although there is controversy concerning the relationship of slg isotype to state of B-cell differentiation (23, 24) , several aspects of isotype acquisition appear to be generally accepted. Specifically, during ontogeny, B cells first express sIgM alone (19, 29, 30) and subsequently express both sIgM and sIgD (31, 32) and, in a proportion of cells, a third isotype as well (23) , apparently independent of encounter with antigen. Cells bearing both sIgM and sIgD may secrete either IgM or IgG upon primary antigenic (or mitogenic) stimulation (33) , during which time sIgD is the first isotype to be lost (34) (35) (36) . In contrast, memory cell precursors ofIgG-secreting cells have been shown to lack sIgD (33, 36) and instead appear to possess sIgG predominantly (33, 37, 38) . Although no extensive investigation of surface isotype vs. differentiation stage was carried out in these studies, our findings are consistent with these data. The predominant isotypic change observed after activation was from cells expressing sIgM and sIgD to cells expressing sIgM and sIgG. Loss of sIgD occurred at approximately the same rate as loss of B2; acquisition of sIgG was a relatively late event ( Table 3 ). The finding (Fig.  2) of a transient increase in B2 expression by peripheral blood B cells after activation provides a further suggestion that these cells are relatively immature in that they can be stimulated to differentiate to the B1+..., B2++ phenotype typical of B cells in secondary lymphoid organs. In this regard, tissue sections of tonsil or appendix stained with anti-B1 or anti-B2 demonstrate clearly that a distinct compartmentalization of B cell subsets exists in B-cell areas, with mantle zone cells reflecting the peripheral blood B cell phenotype and germinal center cells being more differentiated (ref. 39 ; A. Bhan, personal communication). In addition, mantle zone cells, but not B cells in germinal centers, express sIgD whereas the reverse pattern is seen with sIgG. Thus, mantle zone cells may represent recirculating B cells ofthe peripheral blood phenotype; cells within germinal centers may be more mature, perhaps a mixture ofactivated and memory B cells.
The present findings suggest that the B1 and B2 antigens, used in conjunction with conventional B cell markers, can provide useful tools for both experimental and clinical purposes. These include analysis of the process of normal human B lymphocyte differentiation, identification of functional B-cell subpopulations, and categorization of tumors of B-cell lineage.
